Skip Navigation

Japanese Journal of Clinical Oncology 2006 36(2):125; doi:10.1093/jjco/hyi239
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Fukuda, H.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Fukuda, H.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?


© 2006 Foundation for Promotion of Cancer Research

Homepage of the Month

Homepage of the Month

Haruhiko Fukuda

The first 10% of the full text of this article appears below.


   Introduction
 
Homepages are redesigned or modified very frequently; therefore, please note that comments in this section are based on the contents of the homepage at the time of writing.


Figure Removed (Available Only in the Full Text)
View larger version (86K):
[in this window]
[in a new window]
 
 

   New European Guideline for Evaluation of Anticancer Products—European Medicines Agency (EMEA) (http://www.emea.eu.int/)
 
The European Medicines Agency (EMEA) is a decentralized body of the European Union with its headquarters in London. The EMEA . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?